Home / Business and Economy / Weight-Loss Drugs Threaten Beer Sales, Heineken Warns
Weight-Loss Drugs Threaten Beer Sales, Heineken Warns
23 Oct
Summary
- Weight-loss drugs are reducing desire to drink alcohol.
- Venues urged to promote smaller servings and low-alcohol options.
- US households using drugs spent 7% less on alcohol monthly.
Heineken, a major global brewer, has alerted its UK hospitality customers that the surging popularity of weight-loss drugs, such as Ozempic and Wegovy, could significantly impact beer and cider sales. The company's presentation, seen by Reuters, advises pubs and bars to adapt by promoting smaller drink sizes, low- and no-alcohol beverages, and pairing drinks with small plates. This strategic shift aims to mitigate potential declines in customer visits and revenue as GLP-1 drug usage becomes more mainstream.
Evidence suggests these GLP-1 medications reduce the desire to drink alcohol due to increased feelings of fullness and fewer servings. Research indicates that US households using these drugs have reduced their monthly alcohol spending by approximately 7%, with a notable 13.5% decrease in beer expenditure. Despite this emerging trend, some drinks companies, like Diageo and Carlsberg, have downplayed the immediate impact, though recent surveys and interviews with users confirm reduced alcohol consumption.
